(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.

The three biggest winners today are Banco Bradesco, Royal Bank Of Canada, and FuboTV.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Banco Bradesco (BBDO) 3.42 4.94% 2022-09-23 04:09:58
2 Royal Bank Of Canada (RY) 96.08 3.67% 2022-09-23 07:31:50
3 FuboTV (FUBO) 4.03 2.81% 2022-09-23 07:22:07
4 Identiv (INVE) 12.92 1.33% 2022-09-23 04:12:37
5 BCE (BCE) 46.23 0% 2022-09-23 04:10:01
6 NeuroMetrix (NURO) 3.02 0% 2022-09-23 07:07:11
7 Nautilus (NLS) 1.79 0% 2022-09-23 07:01:35
8 Horizon Therapeutics (HZNP) 62.60 -0.05% 2022-09-23 04:12:14
9 Vanguard Short-Term (VGSH) 57.79 -0.16% 2022-09-23 07:07:45
10 Intercontinental Exchange (ICE) 93.79 -0.29% 2022-09-23 07:14:42

The three biggest losers today are FAT Brands, Plug Power, and First Majestic Silver.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 FAT Brands (FAT) 8.24 -4.07% 2022-09-23 07:31:37
2 Plug Power (PLUG) 23.08 -3.61% 2022-09-23 07:28:20
3 First Majestic Silver (AG) 7.08 -3.54% 2022-09-23 07:09:17
4 Yamana Gold (AUY) 4.17 -3.25% 2022-09-23 07:24:57
5 ImmunoGen (IMGN) 4.55 -3.19% 2022-09-23 07:18:20
6 Tattooed Chef (TTCF) 5.33 -3.09% 2022-09-23 07:22:47
7 Astrazeneca (AZN) 54.72 -2.82% 2022-09-23 07:25:03
8 Inovio Pharmaceuticals (INO) 1.72 -2.76% 2022-09-23 07:03:39
9 Beyond Meat (BYND) 14.85 -2.62% 2022-09-23 07:30:55
10 Mizuho Financial Group (MFG) 2.28 -2.56% 2022-09-23 04:37:47

Premarket Winners today

1. Banco Bradesco (BBDO) – Premarket: 4.94%

Banco Bradesco S.A. and its affiliates offer a variety of banking services and products to Brazilian and international individuals and corporations. Two segments of the company are Banking and Insurance. The company offers current, savings and click accounts, as well as vehicle financing, payday loans, mortgage loans and microcredit. It also provides personal and installment credit. Debit and business cards are available. Banco Bradesco S.A. is an American bank based in Osasco Brazil. It was established in 1943.

NYSE ended the session with Banco Bradesco rising 3.46% to $3.26 on Friday, following the last session’s upward trend. NYSE slid 0.84% to $14,116.59, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Banco Bradesco is 61316, 242.52% above its average volume of 17901.

Banco Bradesco’s last close was $3.26, 16.43% under its 52-week high of $3.90.

Banco Bradesco’s Revenue

Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 95.45B for the twelve trailing months.

Volatility

Banco Bradesco’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.58%, a negative 0.21%, and a positive 1.75%, respectively.

Banco Bradesco’s highest amplitude of average volatility was 2.22% (last week), 1.70% (last month), and 1.75% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Banco Bradesco’s stock is considered to be oversold (<=20).

Banco Bradesco’s Stock Yearly Top and Bottom Value

Banco Bradesco’s stock is valued at $3.26 at 08:34 EST, way under its 52-week high of $3.90 and way higher than its 52-week low of $2.45.

Banco Bradesco’s Moving Average

Banco Bradesco’s worth is way above its 50-day moving average of $2.90 and higher than its 200-day moving average of $3.16.

More news about Banco Bradesco.

2. Royal Bank Of Canada (RY) – Premarket: 3.67%

Royal Bank of Canada is a global financial services company that offers diversified banking and investment options. Personal & Commercial Banking offers personal and commercial banking services, such as checking and saving accounts, home equity financing and private lending. The segment provides financial services via branches, automated banktellers, and a mobile sales network. The company’s Wealth Management segment offers a range of strategies and advice to individuals and institutions with high net worth or ultra-high networth. Its Insurance segment provides life, health and home insurance, as well as travel and wealth insurance to individuals, businesses, and groups through RBC’s advice centers and RBC insurance shops. The RBC also has mobile advisors, RBC mobile insurance stores and independent brokers. The Investor & Treasury Services segment offers asset servicing, custody and payments to investors. It also provides fund and investment administration services, including shareholder, private capital performance monitoring and compliance monitoring. Distribution, transaction banking and cash management are some of the services offered by this division. Capital Markets offers investment and corporate banking services as well as advisory, sales, trading, equity and debt origination services to corporations, institutions, asset managers and private equity firms. It was established in Toronto in Canada in 1864.

NYSE ended the session with Royal Bank Of Canada sliding 0.76% to $92.68 on Friday, after five successive sessions in a row of losses. NYSE dropped 0.84% to $14,116.59, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Royal Bank Of Canada is 543027, 32.87% below its average volume of 808925.

Royal Bank Of Canada’s last close was $92.68, 22.39% below its 52-week high of $119.41.

Royal Bank Of Canada’s Sales

Royal Bank Of Canada’s sales growth is a negative 6.4% for the ongoing quarter and 1.5% for the next. The company’s growth estimates for the ongoing quarter is a negative 13.2% and positive 0.9% for the next.

Royal Bank Of Canada’s Revenue

Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 50.42B for the twelve trailing months.

Volatility

Royal Bank Of Canada’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.57%, a negative 0.18%, and a positive 1.18%, respectively.

Royal Bank Of Canada’s highest amplitude of average volatility was 1.46% (last week), 1.32% (last month), and 1.18% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Royal Bank Of Canada’s stock is considered to be overbought (>=80).

Royal Bank Of Canada’s Stock Yearly Top and Bottom Value

Royal Bank Of Canada’s stock is valued at $92.68 at 08:35 EST, way under its 52-week high of $119.41 and higher than its 52-week low of $90.75.

Royal Bank Of Canada’s Moving Average

Royal Bank Of Canada’s worth is under its 50-day moving average of $96.59 and way under its 200-day moving average of $103.94.

More news about Royal Bank Of Canada.

3. FuboTV (FUBO) – Premarket: 2.81%

FuboTV Inc. provides live streaming for entertainment, sports and news content throughout the United States. Customers can access the fuboTV platform via streaming devices as well as SmartTVs and computers. New York is the headquarters of this company.

NYSE ended the session with FuboTV sliding 10.3% to $3.92 on Friday, after two consecutive sessions in a row of losses. NYSE dropped 0.84% to $14,116.59, after three consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for FuboTV is 9840660, 39.54% below its average volume of 16277100.

FuboTV’s last close was $3.92, 88.83% under its 52-week high of $35.10.

FuboTV’s Sales

FuboTV’s sales growth is 102.2% for the present quarter and 99.7% for the next. The company’s growth estimates for the present quarter is a negative 18.6% and positive 5.9% for the next.

FuboTV’s Revenue

Year-on-year quarterly revenue growth grew by 119.9%, now sitting on 638.35M for the twelve trailing months.

Volatility

FuboTV’s last week, last month’s, and last quarter’s current intraday variation average was a positive 5.10%, a negative 1.13%, and a positive 6.22%, respectively.

FuboTV’s highest amplitude of average volatility was 8.14% (last week), 6.29% (last month), and 6.22% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

FuboTV’s stock is considered to be overbought (>=80).

FuboTV’s Stock Yearly Top and Bottom Value

FuboTV’s stock is valued at $3.92 at 08:36 EST, way below its 52-week high of $35.10 and way higher than its 52-week low of $2.49.

FuboTV’s Moving Average

FuboTV’s worth is above its 50-day moving average of $3.60 and way under its 200-day moving average of $13.77.

More news about FuboTV.

4. Identiv (INVE) – Premarket: 1.33%

Identiv, Inc. is a security company. It protects data and things in Americas, Europe, Middle East, Middle East, Asia-Pacific, and Asia-Pacific. It operates two main segments: Identity and Premises. Identity offers solutions and products that enable secure access to information for the logical and cyber security markets. It also protects connected objects with embedded radio-frequency security. Premises provides security solutions such as access control and video surveillance. It sells products via dealers, system integrators and value-added resellers. The former name of the company was Identive Group, Inc., but it changed its name in May 2014 to Identiv, Inc. Identiv, Inc. was established in 1990. It is located in Fremont, California.

NASDAQ ended the session with Identiv sliding 1.54% to $12.75 on Friday, after two sequential sessions in a row of losses. NASDAQ slid 1.37% to $11,066.81, after three consecutive sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Identiv is 53495, 22.94% below its average volume of 69420.

Identiv’s last close was $12.75, 56.03% under its 52-week high of $29.00.

Identiv’s Sales

Identiv’s sales growth is 30.1% for the current quarter and 46.4% for the next.

Identiv’s Revenue

Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 106.67M for the twelve trailing months.

Volatility

Identiv’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.11%, a negative 1.25%, and a positive 2.45%, respectively.

Identiv’s highest amplitude of average volatility was 1.92% (last week), 1.91% (last month), and 2.45% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Identiv’s stock is considered to be overbought (>=80).

Identiv’s Stock Yearly Top and Bottom Value

Identiv’s stock is valued at $12.75 at 08:36 EST, way below its 52-week high of $29.00 and way higher than its 52-week low of $10.70.

Identiv’s Moving Average

Identiv’s value is below its 50-day moving average of $14.06 and way below its 200-day moving average of $16.23.

More news about Identiv.

5. BCE (BCE) – Premarket: 0%

BCE Inc. is a Canadian telecommunications company that offers wireline, Internet and TV services for residential and business customers. Three segments of the company are Bell Wireless, Bell Wireline and Bell Media. Bell Wireless offers voice and data communications products and services as well as electronics consumer products. Bell Wireline offers data services such as internet access, Internet protocol TV (IPTV), long distance and local phone services as well as other products and services. It also provides satellite TV and connectivity services. The segment sells long-distance, local, data and other services to or from resellers. Bell Media provides traditional TV and specialty TV as well as streaming, broadcast, video, audio, and radio services. BCE Inc. was established in Verdun Canada in 1880.

NYSE ended the session with BCE jumping 0.68% to $46.23 on Friday, following the last session’s upward trend. NYSE dropped 0.84% to $14,116.59, after three sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for BCE is 1021550, 13.85% below its average volume of 1185880.

BCE’s last close was $46.23, 22.09% under its 52-week high of $59.34.

The company’s growth estimates for the ongoing quarter is a negative 1.5% and positive 6.2% for the next.

BCE’s Revenue

Year-on-year quarterly revenue growth grew by 2.5%, now sitting on 23.59B for the twelve trailing months.

BCE’s Stock Yearly Top and Bottom Value

BCE’s stock is valued at $46.23 at 08:36 EST, way below its 52-week high of $59.34 and above its 52-week low of $46.12.

BCE’s Moving Average

BCE’s value is under its 50-day moving average of $49.28 and way below its 200-day moving average of $52.03.

More news about BCE.

6. NeuroMetrix (NURO) – Premarket: 0%

NeuroMetrix, Inc. is a healthcare company that designs, builds, and markets medical devices to stimulate and analyze nerve responses for therapeutic and diagnostic purposes. It operates in North America, Europe, Japan, China, Japan, China, Mexico, China, Japan, China, China, Middle East, and Mexico. DPNCheck is a nerve conduction test used for diagnosing peripheral neuropathies such as diabetes peripheral neuropathy. Quell, a wearable device that provides symptomatic relief, and manages chronic pain, are its primary products. ADVANCE, a platform to perform nerve conduction studies, is the company’s main product. It sells its products to primary care doctors, occupational health, primary and internal medicine specialists, as well as primary care physicians. NeuroMetrix, Inc., was founded in 1996. It is located in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix sliding 1.96% to $3.00 on Friday while NASDAQ dropped 1.37% to $11,066.81.

Volume

Today’s last reported volume for NeuroMetrix is 18038, 80.87% below its average volume of 94300.

NeuroMetrix’s last close was $3.00, 80.58% below its 52-week high of $15.45.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 3.4%, now sitting on 8.33M for the twelve trailing months.

Volatility

NeuroMetrix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.79%, a negative 0.20%, and a positive 3.42%, respectively.

NeuroMetrix’s highest amplitude of average volatility was 1.79% (last week), 2.56% (last month), and 3.42% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NeuroMetrix’s stock is considered to be overbought (>=80).

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $3.00 at 08:36 EST, way below its 52-week high of $15.45 and way above its 52-week low of $2.70.

NeuroMetrix’s Moving Average

NeuroMetrix’s value is way under its 50-day moving average of $3.49 and way below its 200-day moving average of $4.13.

More news about NeuroMetrix.

7. Nautilus (NLS) – Premarket: 0%

Nautilus, Inc., is a company that provides fitness solutions. It designs, develops, source, markets, and sells cardio and strength products and accessories. It operates two business segments: Direct and Retail. The company offers cardio products such as treadmills and ellipticals as well as home gyms and dumbbells and barbells. It also has a fitness platform called JRNY. It also licenses its intellectual property and brands. It offers products to customers directly through TV advertising, social media and catalogs. Nautilus, Inc., was established in 1986. It is located in Vancouver, Washington.

NYSE ended the session with Nautilus falling 2.19% to $1.79 on Friday, after five successive sessions in a row of losses. NYSE fell 0.84% to $14,116.59, after three successive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Nautilus is 210853, 57.32% below its average volume of 494123.

Nautilus’s last close was $1.79, 84.3% below its 52-week high of $11.40.

The company’s growth estimates for the present quarter and the next is a negative 265.1% and a negative 220%, respectively.

Nautilus’s Revenue

Year-on-year quarterly revenue growth declined by 41.9%, now sitting on 589.53M for the twelve trailing months.

Volatility

Nautilus’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.45%, a negative 1.68%, and a positive 4.06%, respectively.

Nautilus’s highest amplitude of average volatility was 1.45% (last week), 3.63% (last month), and 4.06% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Nautilus’s stock is considered to be overbought (>=80).

Nautilus’s Stock Yearly Top and Bottom Value

Nautilus’s stock is valued at $1.79 at 08:36 EST, way below its 52-week high of $11.40 and higher than its 52-week low of $1.64.

Nautilus’s Moving Average

Nautilus’s value is way below its 50-day moving average of $2.08 and way below its 200-day moving average of $3.68.

More news about Nautilus.

8. Horizon Therapeutics (HZNP) – Premarket: -0.05%

Horizon Therapeutics Public Limited Company is a biotech company that specializes in the development and commercialization medicines to address severe and rare autoimmune and severe inflammation diseases. It operates two distinct segments: Orphan and Inflammation. The company’s product portfolio includes 12 medications in areas such as gout and ophthalmology. The company markets the intravenous injections TEPEZZA (teprotumumab trbw); KRYSTEXA (pegloticase infusion) and RAVICTI(glycerol penylbutyrate). It also sells PROCYSBI and BUPHENYL tablets for oral and subcutaneous use, and QUINSAIR (levofloxacin), which is an inhalation solution; and UPLIZNA – intravenous injections) to be cdon; The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. The company has agreements to collaborate with HemoShear Therapeutics, LLC. The company is affiliated with HemoShear Therapeutics, LLC, Alpine Immune Sciences, Inc., Halozyme Therapeutics, Inc., and Arrowhead Pharmaceuticals, Inc. The former name of the company was Horizon Pharma Public Limited Company. In May 2019, Horizon Therapeutics Public Limited Company took over. Horizon Therapeutics Public Limited Company was established in 2005. It is located in Dublin, Ireland. Additional offices are in Deerfield, Illinois, Chicago, Illinois, Lake Forest, Illinois, South San Francisco, California, Washington, D.C., Gaithersburg, Maryland, Rockville, Maryland, and Mannheim, Germany.

NASDAQ ended the session with Horizon Therapeutics jumping 0.18% to $62.63 on Friday while NASDAQ slid 1.37% to $11,066.81.

Volume

Today’s last reported volume for Horizon Therapeutics is 2285670, 16.78% below its average volume of 2746860.

Horizon Therapeutics’s last close was $62.63, 48.04% below its 52-week high of $120.54.

Horizon Therapeutics’s Sales

Horizon Therapeutics’s sales growth is 12.4% for the ongoing quarter and 4.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 16.7% and a negative 13.1%, respectively.

Horizon Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 158.5%, now sitting on 3.77B for the twelve trailing months.

Volatility

Horizon Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.00%, a negative 0.04%, and a positive 2.07%, respectively.

Horizon Therapeutics’s highest amplitude of average volatility was 1.45% (last week), 1.91% (last month), and 2.07% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Horizon Therapeutics’s stock is considered to be overbought (>=80).

Horizon Therapeutics’s Stock Yearly Top and Bottom Value

Horizon Therapeutics’s stock is valued at $62.63 at 08:37 EST, way under its 52-week high of $120.54 and above its 52-week low of $57.84.

Horizon Therapeutics’s Moving Average

Horizon Therapeutics’s worth is way under its 50-day moving average of $72.07 and way below its 200-day moving average of $91.29.

More news about Horizon Therapeutics.

9. Vanguard Short-Term (VGSH) – Premarket: -0.16%

NASDAQ ended the session with Vanguard Short-Term dropping 0.16% to $57.88 on Friday while NASDAQ fell 1.37% to $11,066.81.

Volume

Today’s last reported volume for Vanguard Short-Term is 3216650, 0.01% below its average volume of 3217070.

Volatility

Vanguard Short-Term’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.17%, a negative 0.05%, and a positive 0.12%, respectively.

Vanguard Short-Term’s highest amplitude of average volatility was 0.17% (last week), 0.11% (last month), and 0.12% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Vanguard Short-Term’s stock is considered to be overbought (>=80).

More news about Vanguard Short-Term.

10. Intercontinental Exchange (ICE) – Premarket: -0.29%

Intercontinental Exchange, Inc., along with its affiliates, operate regulated exchanges, clearinghouses, and listings venues in commodity, fixed income, equity, and financial markets throughout the United States, Canada, United Kingdom, Europe, Singapore, Israel, Singapore, Israel, as well as other countries. The company operates in three main segments, namely Exchanges, Fixed Income, Data Services and Mortgage Technology. It operates exchanges that allow trading and clearing of a variety of financial derivatives contracts. Fixed income data, analytic and fixed income execution are provided. CDS clearing is also offered. The company also offers a proprietary, comprehensive mortgage origination platform that serves residential mortgage loans. It facilitates secure data exchange and provides connectivity to the mortgage supply chains. Intercontinental Exchange, Inc., was established in 2000. It is located in Atlanta, Georgia.

NYSE ended the session with Intercontinental Exchange jumping 0.48% to $94.06 on Friday, following the last session’s upward trend. NYSE dropped 0.84% to $14,116.59, after three consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Intercontinental Exchange is 2024130, 18.46% below its average volume of 2482570.

Intercontinental Exchange’s last close was $94.06, 32.71% under its 52-week high of $139.79.

The company’s growth estimates for the current quarter is 9.5% and a drop 0.8% for the next.

Intercontinental Exchange’s Revenue

Year-on-year quarterly revenue growth grew by 5.7%, now sitting on 7.25B for the twelve trailing months.

Volatility

Intercontinental Exchange’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.79%, a negative 0.57%, and a positive 1.46%, respectively.

Intercontinental Exchange’s highest amplitude of average volatility was 2.46% (last week), 1.37% (last month), and 1.46% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Intercontinental Exchange’s stock is considered to be overbought (>=80).

Intercontinental Exchange’s Stock Yearly Top and Bottom Value

Intercontinental Exchange’s stock is valued at $94.06 at 08:37 EST, way under its 52-week high of $139.79 and above its 52-week low of $90.05.

Intercontinental Exchange’s Moving Average

Intercontinental Exchange’s value is under its 50-day moving average of $102.07 and way below its 200-day moving average of $115.42.

More news about Intercontinental Exchange.

Premarket Losers Today

1. FAT Brands (FAT) – Premarket: -4.07%

FAT Brands Inc. is a franchising firm that acquires and develops fast-casual, casual and casual restaurant brands. It owned 17 restaurant brands as of April 18, 2022. These include Round Table Pizza and Fatburger as well as Marble Slab Creamery and Twin Peaks. It was founded in 2017, and its headquarters is in Beverly Hills. FAT Brands Inc. is a subsidiary fo Fog Cutter Holdings LLC.

NASDAQ ended the session with FAT Brands sliding 0.93% to $8.55 on Friday, following the last session’s downward trend. NASDAQ slid 1.37% to $11,066.81, after three consecutive sessions in a row of losses, on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for FAT Brands is 8639, 28.3% below its average volume of 12050.

FAT Brands’s last close was $8.55, 34.88% under its 52-week high of $13.13.

The company’s growth estimates for the current quarter is a negative 150% and positive 73.9% for the next.

FAT Brands’s Revenue

Year-on-year quarterly revenue growth grew by 1141.1%, now sitting on 304.14M for the twelve trailing months.

Volatility

FAT Brands’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.04%, a negative 0.41%, and a positive 2.00%, respectively.

FAT Brands’s highest amplitude of average volatility was 1.22% (last week), 1.53% (last month), and 2.00% (last quarter), respectively.

FAT Brands’s Stock Yearly Top and Bottom Value

FAT Brands’s stock is valued at $8.55 at 08:37 EST, way below its 52-week high of $13.13 and way above its 52-week low of $5.47.

FAT Brands’s Moving Average

FAT Brands’s worth is below its 50-day moving average of $8.65 and higher than its 200-day moving average of $8.32.

More news about FAT Brands.

2. Plug Power (PLUG) – Premarket: -3.61%

Plug Power Inc. provides end-to-end hydrogen and zero emission fuel cell solutions to supply chain and logistics, on-road electric cars, the stationary power market and other markets in North America as well as internationally. The company is involved in the creation of a green hydrogen ecosystem that includes green hydrogen storage, delivery and production as well as energy generation via mobile and stationary devices. It offers fuel cell/battery hybrid technology, fuel cell/battery hybrid, proton exchange membrane, fuel cell, fuel processing, and fuel cell/petroleum technologies as well as associated hydrogen and green-hydrogen generation, storage and dispensing infrastructure. GenDrive is a hydrogen-fueled, PEM fuel-cell system, which provides power for material handling electric cars; GenFuel is a liquid fueling delivery system, generation and storage system. GenCare offers an on-site maintenance program that uses the Internet of Things to maintain and service GenDrive fuel cells systems and GenSure fuel cells systems. GenFuel hydrogen storage products and GenFuel fuel cell engines. GenSure offers stationary fuel cell solutions that provide modular PEM fuel-cell power to meet the grid support power needs of the utility, telecom, utilities. GenKey is a turn-key integrated solution to transitioning from fuel cell power. It also offers ProGen, which is a fuel cells stack and engine technology that can be used in stationary and mobility fuel cell systems and in engines for electric delivery vans. GenFuel Electrolyzers are hydrogen generators specifically designed for clean hydrogen production. It sells products via a direct sales force, original equipment makers, and dealer networks. The company has agreements with Airbus, Lhyfe, Edison Motors and Phillips 66. It also works with Apex Clean Energy, BAE Systems, Universal Hydrogen Co. It was established in 1997. The company is located in Latham in New York.

NASDAQ ended the session with Plug Power falling 6.19% to $23.94 on Friday, after five sequential sessions in a row of losses. NASDAQ dropped 1.37% to $11,066.81, after three successive sessions in a row of losses, on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Plug Power is 16222700, 25.1% below its average volume of 21661000.

Plug Power’s last close was $23.94, 48.52% under its 52-week high of $46.50.

The company’s growth estimates for the ongoing quarter is a negative 11.1% and positive 10.5% for the next.

Plug Power’s Revenue

Year-on-year quarterly revenue growth grew by 95.7%, now sitting on 571.19M for the twelve trailing months.

Volatility

Plug Power’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.54%, a positive 0.04%, and a positive 4.62%, respectively.

Plug Power’s highest amplitude of average volatility was 1.90% (last week), 3.02% (last month), and 4.62% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Plug Power’s stock is considered to be overbought (>=80).

Plug Power’s Stock Yearly Top and Bottom Value

Plug Power’s stock is valued at $23.94 at 08:37 EST, way under its 52-week high of $46.50 and way higher than its 52-week low of $12.70.

Plug Power’s Moving Average

Plug Power’s value is under its 50-day moving average of $24.42 and above its 200-day moving average of $23.46.

More news about Plug Power.

3. First Majestic Silver (AG) – Premarket: -3.54%

First Majestic Silver Corp. is engaged in exploration, development and production of mineral properties. Its primary focus is on North American silver and gold production. The company holds 100% interest in San Dimas Silver/Gold Mine, which covers an area covering 71,868 ha in Durango, Sinaloa, and Santa Elena Silver/Gold Mines. Jerritt Canyon, Nevada, has a gold mine covering approximately 30,821 ha. La Encantada Silver Mine, covering 4,076 ha in Coahuila. It also owns 1,343 acres of surface land. It also owns 100% of the La Parrilla Silver Mine, which covers an area covering 69,478 ha in Durango, the Del Toro Silver Mine, consisting of 3,815 Ha of mining concessions, and 219 Ha of surface rights in Zacatecas, the San Martin Silver Mine, with 33 mining concessions, and 39,714 ha, located in Jalisco, and the La Guitarra Silver Mine, that covers an additional 39,714 ha. It also holds an interest in the Springpole gold-silver project that covers approximately 41,913 ha in Ontario, Canada. First Majestic Resource Corp. was the company’s name before it changed to First Majestic Silver Corp. on November 2006. First Majestic Silver Corp. is an American corporation that was founded in 1979. Its headquarters are located in Vancouver, Canada.

NYSE ended the session with First Majestic Silver dropping 3.48% to $7.34 on Friday while NYSE slid 0.84% to $14,116.59.

Volume

Today’s last reported volume for First Majestic Silver is 5644400, 5.57% below its average volume of 5977350.

First Majestic Silver’s last close was $7.34, 49.97% below its 52-week high of $14.67.

First Majestic Silver’s Sales

First Majestic Silver’s sales growth is 12.3% for the ongoing quarter and 58% for the next. The company’s growth estimates for the present quarter is a negative 60% and positive 214.3% for the next.

First Majestic Silver’s Revenue

Year-on-year quarterly revenue growth grew by 56%, now sitting on 640.43M for the twelve trailing months.

Volatility

First Majestic Silver’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.44%, a negative 0.24%, and a positive 3.13%, respectively.

First Majestic Silver’s highest amplitude of average volatility was 5.00% (last week), 3.41% (last month), and 3.13% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

First Majestic Silver’s stock is considered to be overbought (>=80).

First Majestic Silver’s Stock Yearly Top and Bottom Value

First Majestic Silver’s stock is valued at $7.34 at 08:37 EST, way under its 52-week high of $14.67 and way above its 52-week low of $6.31.

First Majestic Silver’s Moving Average

First Majestic Silver’s worth is under its 50-day moving average of $7.53 and way below its 200-day moving average of $9.89.

More news about First Majestic Silver.

4. Yamana Gold (AUY) – Premarket: -3.25%

Yamana Gold Inc. and its affiliates operate as precious metal producers. The company has silver and gold production as well as exploration and development properties. It also holds land positions in the Americas including Canada, Brazil and Chile. Yamana Resources Inc. was the company’s previous name. In August 2003, Yamana Gold Inc. took over its operations. Yamana Gold Inc. is located in Toronto, Canada.

NYSE ended the session with Yamana Gold rising 0.58% to $4.31 on Friday, after two successive sessions in a row of gains. NYSE dropped 0.84% to $14,116.59, after three consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Yamana Gold is 11869700, 23.82% below its average volume of 15582000.

Yamana Gold’s last close was $4.31, 32.66% under its 52-week high of $6.40.

Yamana Gold’s Sales

Yamana Gold’s sales growth is 4.7% for the ongoing quarter and a decline by 5.8% for the next.

Yamana Gold’s Revenue

Year-on-year quarterly revenue growth grew by 11%, now sitting on 1.88B for the twelve trailing months.

Volatility

Yamana Gold’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.09%, a negative 0.82%, and a positive 2.25%, respectively.

Yamana Gold’s highest amplitude of average volatility was 2.09% (last week), 2.60% (last month), and 2.25% (last quarter), respectively.

Yamana Gold’s Stock Yearly Top and Bottom Value

Yamana Gold’s stock is valued at $4.31 at 08:37 EST, way under its 52-week high of $6.40 and way above its 52-week low of $3.70.

Yamana Gold’s Moving Average

Yamana Gold’s worth is under its 50-day moving average of $4.72 and way below its 200-day moving average of $4.86.

More news about Yamana Gold.

5. ImmunoGen (IMGN) – Premarket: -3.19%

ImmunoGen, Inc., is a biotech company in clinical stage. It develops ADC therapies for cancer. Mirvetuximab Soravtansine is an ADC which targets folate receptor alpha (FRa) and is currently in Phase III clinical trials. Pivekimab Sunirine is a CD123-targeting ADC and is currently in Phase II clinical trials to treat acute myeloid and blastic plasmacytoid cell neplasma. Preclinical programs for the company include IMGC936, an ADC co-developed with MacroGenics, Inc., and IMGN151, a anti-FRa product candidate. Collaborations include Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CymX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. ImmunoGen, Inc., was established in 1980 and has its headquarters in Waltham, Massachusetts.

NASDAQ ended the session with ImmunoGen sliding 0.53% to $4.70 on Friday, after three sequential sessions in a row of losses. NASDAQ fell 1.37% to $11,066.81, after three successive sessions in a row of losses, on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for ImmunoGen is 1383750, 55.4% below its average volume of 3103090.

ImmunoGen’s last close was $4.70, 39.51% under its 52-week high of $7.77.

ImmunoGen’s Sales

ImmunoGen’s sales growth is a negative 4.5% for the current quarter and 22.6% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 40% and a negative 38.9%, respectively.

ImmunoGen’s Revenue

Year-on-year quarterly revenue growth declined by 16.4%, now sitting on 89.44M for the twelve trailing months.

Volatility

ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.39%, a negative 0.52%, and a positive 3.68%, respectively.

ImmunoGen’s highest amplitude of average volatility was 2.92% (last week), 3.34% (last month), and 3.68% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

ImmunoGen’s stock is considered to be overbought (>=80).

ImmunoGen’s Stock Yearly Top and Bottom Value

ImmunoGen’s stock is valued at $4.70 at 08:37 EST, way below its 52-week high of $7.77 and way above its 52-week low of $3.10.

ImmunoGen’s Moving Average

ImmunoGen’s worth is way below its 50-day moving average of $5.40 and way under its 200-day moving average of $5.28.

More news about ImmunoGen.

6. Tattooed Chef (TTCF) – Premarket: -3.09%

Tattooed Chef, Inc., is a company that produces and sells frozen food products. The company supplies American retailers with plant-based products. It offers ready-to cook bowls and zucchini spirals as well as acai, smoothie, and cauliflower pizza. The company’s frozen foods are sold under the Tattooed Chef and private label brands. It had approximately 14,000 outlets as of December 31, 2021. Tattooed Chef, Inc. has its headquarters in Paramount, California.

NASDAQ ended the session with Tattooed Chef jumping 0.36% to $5.50 on Friday, after two sequential sessions in a row of gains. NASDAQ dropped 1.37% to $11,066.81, after three successive sessions in a row of losses, on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Tattooed Chef is 773451, 17.25% above its average volume of 659642.

Tattooed Chef’s last close was $5.50, 78.3% below its 52-week high of $25.35.

Tattooed Chef’s Sales

Tattooed Chef’s sales growth is 26.4% for the current quarter and 15.4% for the next. The company’s growth estimates for the present quarter is 78.1% and a drop 33.3% for the next.

Tattooed Chef’s Revenue

Year-on-year quarterly revenue growth grew by 30%, now sitting on 213.43M for the twelve trailing months.

Volatility

Tattooed Chef’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.99%, a negative 1.17%, and a positive 3.67%, respectively.

Tattooed Chef’s highest amplitude of average volatility was 1.99% (last week), 4.49% (last month), and 3.67% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Tattooed Chef’s stock is considered to be overbought (>=80).

Tattooed Chef’s Stock Yearly Top and Bottom Value

Tattooed Chef’s stock is valued at $5.50 at 08:37 EST, below its 52-week low of $5.84.

Tattooed Chef’s Moving Average

Tattooed Chef’s worth is way below its 50-day moving average of $9.89 and way under its 200-day moving average of $14.80.

More news about Tattooed Chef.

7. Astrazeneca (AZN) – Premarket: -2.82%

AstraZeneca PLC is a biopharmaceutical firm that focuses on developing, manufacturing and marketing prescription drugs. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Synagis is a respiratory syncytialvirus treatment; Fluenz Tetra/FluMist quadrivalent for Influenza; Serocort IR/Seroquel XR to treat schizophrenia bipolar disorder; Nexium and Losec/Prilosec are gastroenterology treatments; Vaxzevria, Soliris and Strensiq are covid-19 medications. Through distributors and representative offices located in Europe, Americas, Asia and Africa, the company provides primary and specialty care doctors with services. The company has a partnership agreement with Regeneron Pharmaceuticals, Inc. for research, development, and marketing small molecule medications for obesity. Neurimmune AG will develop and market NI006 and Ionis Pharmaceuticals, Inc. for eplontersen, a liver targeted antisense treatment in Phase III for treatment of transthyretin. Proteros Biostructures GmbH and Sierra Oncology, Inc. will jointly develop and commercialize AZD5153. The company used to be known as Zeneca Group PLC. In April 1999, it changed its name from AstraZeneca PLC. AstraZeneca Plc was founded in 1992. It is located in Cambridge, United Kingdom.

NYSE ended the session with Astrazeneca sliding 0.24% to $56.31 on Friday, after five sequential sessions in a row of losses. NYSE dropped 0.84% to $14,116.59, after three sequential sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Astrazeneca is 6792560, 8.64% above its average volume of 6252170.

Astrazeneca’s last close was $56.31, 21.46% under its 52-week high of $71.70.

Astrazeneca’s Sales

Astrazeneca’s sales growth is 27.7% for the present quarter and 5.9% for the next. The company’s growth estimates for the current quarter and the next is 71.1% and 37%, respectively.

Astrazeneca’s Revenue

Year-on-year quarterly revenue growth grew by 31%, now sitting on 44.04B for the twelve trailing months.

Volatility

Astrazeneca’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.17%, a negative 0.67%, and a positive 1.26%, respectively.

Astrazeneca’s highest amplitude of average volatility was 1.91% (last week), 1.35% (last month), and 1.26% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Astrazeneca’s stock is considered to be overbought (>=80).

Astrazeneca’s Stock Yearly Top and Bottom Value

Astrazeneca’s stock is valued at $56.31 at 08:37 EST, way below its 52-week high of $71.70 and higher than its 52-week low of $53.63.

Astrazeneca’s Moving Average

Astrazeneca’s worth is way below its 50-day moving average of $64.82 and way below its 200-day moving average of $62.64.

More news about Astrazeneca.

8. Inovio Pharmaceuticals (INO) – Premarket: -2.76%

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, including anal and cervical dysplasia, vulvar and cervical precancers; HPV associated cancers such as cervical and anal papillomatosis, head and neck cancer, vaginal cancer, HIV, Ebola, Middle East Respiratory syndrome (MERS), and Lassa fever. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, The Wistar Institute of Research, Thermo Fisher Military Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, Thermo Fisher Research, and Thermo Fisher to support the Wistar Institute of Research, Thermo Fisher and Thero Fisher and Thermo Fisher a Fisher Scientific, Thermo Fisher Research, Thermo Fisher ' and Thermo and Thermo To support the investigational DNA vaccine, INO-4800 for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.

NASDAQ ended the session with Inovio Pharmaceuticals sliding 2.21% to $1.77 on Friday while NASDAQ fell 1.37% to $11,066.81.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 2671300, 55.36% below its average volume of 5984140.

Inovio Pharmaceuticals’s last close was $1.77, 80.07% below its 52-week high of $8.88.

Inovio Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth declined by 46.4%, now sitting on 1.6M for the twelve trailing months.

Volatility

Inovio Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.48%, a negative 1.36%, and a positive 5.57%, respectively.

Inovio Pharmaceuticals’s highest amplitude of average volatility was 5.10% (last week), 4.47% (last month), and 5.57% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).

Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $1.77 at 08:38 EST, way under its 52-week high of $8.88 and way higher than its 52-week low of $1.38.

Inovio Pharmaceuticals’s Moving Average

Inovio Pharmaceuticals’s worth is way under its 50-day moving average of $2.19 and way below its 200-day moving average of $3.38.

More news about Inovio Pharmaceuticals.

9. Beyond Meat (BYND) – Premarket: -2.62%

Beyond Meat, Inc. produces, markets, sells and distributes plant-based meat products throughout the United States as well as internationally. It sells various plant-based meat products on the following platforms: beef, pork and poultry. The company sells products via grocery, bulk merchandiser, club shop, convenience store, natural retailer, direct-to-consumer channels and various food-away from-home channels such as restaurants, foodservice outlets and schools. The former name of the company was Savage River, Inc., but it changed its name in September 2018 to Beyond Meat, Inc. Beyond Meat, Inc. was established in 2009. It is located in El Segundo, California.

NASDAQ ended the session with Beyond Meat sliding 4.06% to $15.25 on Friday while NASDAQ dropped 1.37% to $11,066.81.

Volume

Today’s last reported volume for Beyond Meat is 5611640, 65.67% above its average volume of 3387190.

Beyond Meat’s last close was $15.25, 86.79% below its 52-week high of $115.48.

Beyond Meat’s Sales

Beyond Meat’s sales growth is 1.2% for the ongoing quarter and 38.1% for the next. The company’s growth estimates for the current quarter and the next is a negative 280.6% and a negative 12.6%, respectively.

Beyond Meat’s Revenue

Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 465.99M for the twelve trailing months.

Volatility

Beyond Meat’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.31%, a negative 3.23%, and a positive 4.36%, respectively.

Beyond Meat’s highest amplitude of average volatility was 4.97% (last week), 4.55% (last month), and 4.36% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Beyond Meat’s stock is considered to be overbought (>=80).

Beyond Meat’s Stock Yearly Top and Bottom Value

Beyond Meat’s stock is valued at $15.25 at 08:38 EST, way under its 52-week low of $18.18.

Beyond Meat’s Moving Average

Beyond Meat’s value is way under its 50-day moving average of $29.95 and way below its 200-day moving average of $42.41.

More news about Beyond Meat.

10. Mizuho Financial Group (MFG) – Premarket: -2.56%

Mizuho Financial Group, Inc., along with its subsidiaries, is involved in trust, securities, banking, and other financial services, in Japan, Japan, Europe, Asia/Oceania, as well as internationally. The company operates in five different segments: Retail & Business Banking Company; Corporate & Institutional Company; Global Corporate Company; Global Markets Company; and Asset Management Company. It offers deposit products, syndicated, housing and card loans, business matching services, as well as advisory services in relation to overseas expansions and mergers and acquisitions. The company also provides consulting services such as asset management, asset succession and payroll services. It sells lottery tickets from prefectures or ordinance-designated municipalities. It also offers financial solutions such as bonds and risk-hedging products. Corporate customers can use it to help them fund-raise, invest management and plan their financial futures. It offers solutions that are based on their business strategy and capital management. Real estate agency services. Advisory services, including advice and proposals for various financial products. The company also offers consulting and services for institutional investors, as well as sales and trading services. The company also offers products and services in the areas of trust, structured finance and securitization, stock transfers, and pension; as well as securities services, research, private banking and other information technology-related services. Mizuho Financial Group, Inc., was established in Tokyo, Japan in 2003.

NYSE ended the session with Mizuho Financial Group jumping 1.08% to $2.34 on Friday while NYSE slid 0.84% to $14,116.59.

Volume

Today’s last reported volume for Mizuho Financial Group is 702977, 57.87% below its average volume of 1668760.

Mizuho Financial Group’s last close was $2.34, 23.03% under its 52-week high of $3.04.

Mizuho Financial Group’s Revenue

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 2.53T for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Mizuho Financial Group’s stock is considered to be overbought (>=80).

Mizuho Financial Group’s Stock Yearly Top and Bottom Value

Mizuho Financial Group’s stock is valued at $2.34 at 08:38 EST, way under its 52-week high of $3.04 and above its 52-week low of $2.15.

Mizuho Financial Group’s Moving Average

Mizuho Financial Group’s value is higher than its 50-day moving average of $2.34 and below its 200-day moving average of $2.49.

More news about Mizuho Financial Group.

Stay up to date with our premarket winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here